Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Our team collaborates with insurers like UnitedHealthcare, Cigna, Blue Cross Blue Shield, and more, streamlining the prior authorization process
Retatrutide is an investigational GLP-1, GIP, and glucagon triple receptor agonist currently in Phase 3 trials
adults in January 2026 via Pollfish, an online survey platform
But if the scale has been genuinely flat for three to four consecutive weeks and your habits havent changed, the dose may simply not be generating enough of a deficit to keep things moving
US$ 23.70
US$ 24.55
US$ 25.78
US$ 22.34
US$ 23.31
